Wright Investors Service Inc. Has $6.29 Million Stake in Gilead Sciences, Inc. $GILD

Wright Investors Service Inc. increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 56,624 shares of the biopharmaceutical company’s stock after purchasing an additional 5,677 shares during the period. Gilead Sciences makes up approximately 1.8% of Wright Investors Service Inc.’s portfolio, making the stock its 10th biggest holding. Wright Investors Service Inc.’s holdings in Gilead Sciences were worth $6,285,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of GILD. Railway Pension Investments Ltd boosted its holdings in shares of Gilead Sciences by 3.1% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock worth $157,139,000 after purchasing an additional 42,200 shares in the last quarter. TriaGen Wealth Management LLC purchased a new stake in Gilead Sciences in the third quarter worth approximately $1,274,000. Invesco Ltd. grew its position in Gilead Sciences by 33.5% during the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after acquiring an additional 3,394,330 shares during the last quarter. Sivik Global Healthcare LLC raised its stake in shares of Gilead Sciences by 25.0% during the second quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $5,544,000 after acquiring an additional 10,000 shares in the last quarter. Finally, One Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 34.8% in the 2nd quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock worth $1,016,000 after acquiring an additional 2,364 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on GILD shares. JPMorgan Chase & Co. increased their target price on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Cantor Fitzgerald restated an “overweight” rating and set a $135.00 price target on shares of Gilead Sciences in a research report on Friday, October 31st. Morgan Stanley reduced their price objective on Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating on the stock in a research note on Tuesday. HSBC increased their target price on Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a report on Wednesday, December 10th. Finally, TD Cowen lifted their price target on Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $133.16.

Gilead Sciences Trading Down 2.3%

GILD opened at $121.26 on Friday. Gilead Sciences, Inc. has a one year low of $90.82 and a one year high of $128.70. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The business has a 50 day simple moving average of $123.24 and a two-hundred day simple moving average of $117.92. The firm has a market capitalization of $150.44 billion, a price-to-earnings ratio of 18.80, a PEG ratio of 0.65 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were issued a $0.79 dividend. The ex-dividend date was Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.6%. Gilead Sciences’s dividend payout ratio is 48.99%.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.86, for a total value of $3,524,080.00. Following the completion of the sale, the insider directly owned 107,193 shares of the company’s stock, valued at approximately $13,491,310.98. This trade represents a 20.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Deborah H. Telman sold 53,646 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the transaction, the executive vice president owned 43,676 shares in the company, valued at $5,365,596.60. This represents a 55.12% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 130,757 shares of company stock worth $16,205,752. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.